Found vs IVIM Health vs MEDVi (2026)

On tirzepatide, the order is IVIM Health↗ ($278) → Found ($289) → MEDVi↗ ($399) — gaps of $11 and then $110 a month, a $1,452 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

IVIM Health: the record, condensed

IVIM Health’s tirzepatide program bills $278 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The structure is tiered: the advertised entry point is $208, but the maintenance figure — the one a full year is actually billed at — is $278. That $70 gap between the ad and the anniversary is the single most important line in this record.

The all-in figure already contains a compulsory $75 monthly membership. That is the honest way to quote it: a bundled price is only misleading when its parts are advertised separately, and here the medication-only $203 would be exactly that kind of mirage.

Context for that figure: it ranks #3 of 17 in the verified tirzepatide index — $63/month above the floor (NexLife↗, $215) — and sits $171 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $3,336.

IVIM Health’s semaglutide program bills $149 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The figure is quoted at maintenance without a separate teaser tier, which keeps the arithmetic honest by default.

The all-in figure already contains a compulsory $75 monthly membership. That is the honest way to quote it: a bundled price is only misleading when its parts are advertised separately, and here the medication-only $74 would be exactly that kind of mirage.

To place the number: #3 of 20 verified programs, with the floor $16/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $200 a month. A year at this figure: $1,788 monthly-billed.

Operationally at IVIM Health: shipping included; commitment membership mandatory for duration; cancellation membership mandatory; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the IVIM Health page · visit IVIM Health ↗

Found: the record, condensed

Start with the load-bearing figure: $289 a month, all-in, is what Found charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #6 of 17 in the verified tirzepatide index — $74/month above the floor (NexLife, $215) — and sits $160 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,468.

On semaglutide, the number that matters at Found is $289 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $289 is the whole subscription, which makes Found unusually easy to compare and unusually easy to leave.

To place the number: #15 of 20 verified programs, with the floor $156/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $60 a month. A year at this figure: $3,468 monthly-billed.

Operationally at Found: shipping included; commitment none month-to-month; prepaid terms for lowest rate; cancellation membership recurs; prepaid terms are paid up front; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Found page · visit Found ↗

MEDVi: the record, condensed

MEDVi’s tirzepatide program bills $399 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #14 of 17 verified programs, with the floor $184/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.

MEDVi’s semaglutide program bills $299 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $299 is the whole subscription, which makes MEDVi unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #18 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

§ The three-way read

Prices, gaps, and what sits inside them

IVIM Health holds the low ground at $278 (its $75 membership already inside). Found follows at $289 (+$11/mo, $132/yr). MEDVi tops the trio at $399 (+$121/mo over the leader, $1,452/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles nothing: IVIM Health $149 → Found $289 → MEDVi $299 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: IVIM Health ($278); cheapest 12-month path: IVIM Health ($3,336); simplest billing (no membership): Found and MEDVi; dose-flat structure: Found and MEDVi; cheapest semaglutide of the three: IVIM Health ($149).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: IVIM Health vs Found · IVIM Health vs MEDVi · Found vs MEDVi.

§ Structure, three ways

Everything besides the three prices

Memberships: IVIM Health $75/mo (inside its figure); Found none; MEDVi none. Structures: IVIM Health step/tiered; Found dose-flat; MEDVi dose-flat. Pharmacies: IVIM Health not named; Found not named; MEDVi not named. States: IVIM Health — not published; Found — most states; MEDVi — priced differently in CA/NC on some plans. Exit terms: IVIM Health — membership mandatory; Found — membership recurs; prepaid terms are paid up front; MEDVi — 12-month plan applies to lowest rate.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: IVIM Health source-verified (2026-08-05); Found third-party reported (2026-08-05); MEDVi source-verified (2026-08-05).

The trio on semaglutide, across time

3 mo: IVIM Health $447 vs Found $867 vs MEDVi $897 6 mo: IVIM Health $894 vs Found $1,734 vs MEDVi $1,794 12 mo: IVIM Health $1,788 vs Found $3,468 vs MEDVi $3,588 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

IVIM Health: $3,336/yr monthly-billed; Found: $3,468/yr monthly-billed; MEDVi: $4,788/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $2,904 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

Work it as eliminations rather than a beauty contest. MEDVi enters owing an explanation: $121/month above IVIM Health compounds to $1,452 a year — real therapy-months of money — so its record has to name what the premium buys (structure the cheaper two lack) or it exits first. Found survives the first cut only to face the harder question — whether its dose-flat structure removes titration repricing is worth $11 a month to you — because a middle option that cannot answer it is just the expensive option with better camouflage. IVIM Health is what remains: the arithmetic answer at $278, dethroned only by a state gap, a structural need, or a prescriber’s judgment — the three things this page deliberately cannot decide.

The same trio on best published rate: IVIM Health $278 → Found $289 → MEDVi $399 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — IVIM Health $834, Found $867, MEDVi $1,197; 6 months — IVIM Health $1,668, Found $1,734, MEDVi $2,394. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

Grade the three records before trusting the three prices. On the five-point disclosure checklist (price, pharmacy, states, cancellation, source-verification): IVIM Health 4/5 · Found 3/5 · MEDVi 4/5. The gap between IVIM Health (4/5) and Found (3/5) is itself information: undisclosed axes are where the questions in each provider’s review earn their keep. No axis splits them, a small collective credit. Every score is a computation from the dataset, contestable at the corrections desk like any other figure.

The three-way verdict compresses cleanly: IVIM Health is the default on arithmetic; Found earns the middle only where its structure (flat pricing) solves something the floor does not; and MEDVi’s $121/month premium over the leader — $1,452 a year, roughly 5.2 extra months of therapy at the floor rate — needs a named justification from its record, not a vibe. Insurance coverage, where it exists, outranks all three.